This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
NIHR HSRIC. Sofosbuvir, GS-9857 and velpatasvir triple therapy for chronic hepatitis C. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016
Hepatitis C is a virus that causes inflammation of the liver. The virus is present in the blood of people with the infection, and this can infect others that come into contact with it. The virus is most commonly passed on by needles contaminated with infected blood, but it is also spread occasionally through unprotected sex. Most people with hepatitis C will have it for many years and they may or may not have symptoms. If the virus is untreated, it can lead to serious liver disease, such as liver cirrhosis and cancer.
Sofosbuvir, GS-9857 and velpatasvir is a new combination of drugs that is taken by mouth as a single tablet to treat hepatitis C infection. Some studies have suggested that this combination drug can clear the body of the virus at least as well as treatment already available and in a shorter time. It may also be helpful for people whose infection has not been cured by current treatments. More studies are trying to show that the drug is safe to use.
If sofosbuvir, GS-9857 and velpatasvir fixed dose combination is licensed for use in the UK, it could be a new treatment option for people with hepatitis C virus, regardless of whether they have already received treatment.
Subject indexing assigned by CRD
Antiviral Agents; Hepatitis C, Chronic; Humans; Sofosbuvir; Uridine Monophosphate
Country of organisation
An English language summary is available.
Address for correspondence
NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: firstname.lastname@example.org
Date abstract record published